Trial Profile
A phase 3, multi-center, open label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Asciminib (Primary) ; Bosutinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASCEMBL
- Sponsors Novartis; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 12 Dec 2023 Results assessing Impact of Mutations in Blood Cancer Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (cutoff: March 22, 2023,n=233)data from pts who experienced failure on Bosutinib and switched to Asciminib ,presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results (n=97)of treatment patterns and real-world clinical outcomes in USA, presented at the 65th American Society of Hematology Annual Meeting and Exposition